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 Abstract As populations age and the prevalence 
of cognitive impairment increases, healthcare 
professionals and researchers require short, validated 
cognitive screening instruments (CSIs). As part the 
EIP-on-AHA Twinning Support Scheme (2016), four 
reference sites developed the RAPid COmmunity 
COGnitive screening Programme (RAPCOG) 
twinning project to validate translated versions of the 
Quick Mild Cognitive Impairment (Qmci) screen that 
could be adapted quickly for use with future eHealth 
screening and assessment programmes. Here we 
present the cultural adaption and translation of the 
Qmci-Portuguese (Qmci-P) screen as part of 
RAPCOG and explore its subsequent validation 
against two commonly-used CSIs (MMSE-P and 
MoCA-P) with 93 participants aged ≥65, attending 
ten day care centres or resident in two long-term care 
institutions; median age 74 (+/-15), 66% female. The 
Qmci-P’s internal consistency was high (Cronbach’s 
Alpha 0.82), compared with the MoCA (0.79) and 
SMMSE (0.54). Qmci-P screen scores moderately 
correlated with the SMMSE (r=0.61, 95% CI:0.45-
0.72, p<0.001) and MoCA (r=0.63, 95% CI:0.36-
0.80, p<0.001). The Qmci-P screen demonstrates 
high internal consistency and concurrent validity 
against more established CSIs and given its brevity 
(3-5mins), may be preferable for use in community 
settings. This project shows the potential of the EIP-
on-AHA Twinning initiative to promote the scaling-
up of innovative good practices. 
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I.  INTRODUCTION 
 
 Dementia is a growing and important public 
health concern [1, 2] associated with an increased risk of 
adverse healthcare outcomes [2], elevated expenditure [3], 
and a greater number of years lived and lost with 
disability [4]. Multi-dimensional intervention strategies 
introduced before the onset of functional impairment may 
slow cognitive decline [5]. Although there is insufficient 
evidence to support routine cognitive screening among 
asymptomatic older adults [6, 7], identifying those with 
subjective decline and mild cognitive impairment (MCI) 
may be important [8, 9].  
Currently, there is no consensus on which 
screening instrument should be used to detect cognitive 
impairment [7], particularly MCI [10], though healthcare 
professionals express a preference for brief and easy-to-
use cognitive screening instruments (CSI) [11, 12]. The 
Quick Mild Cognitive Impairment (Qmci) screen 
(www.qmci.ie), a short (3-5 minutes) CSI designed to 
differentiate normal cognition from MCI and early 
dementia [13], is sensitive across the spectrum of 
cognitive impairment [14, 15, 16] and is validated in 
multiple settings, countries and languages [17-24]. It may 
be an ideal CSI to rapidly screen and triage older adults 
for further assessment. Despite this, it is not translated or 
validated in many European Union (EU) countries.  
The European Innovation Partnership on Active 
and Healthy Ageing (EIP-on-AHA), launched in 2010, 
aims to achieve a triple win of improved health and 
quality of life for older adults, sustainable health systems 
and an enhanced and competitive healthcare marketplace 
[25]. Dedicated action groups under its umbrella have 
created good practice initiatives called commitments with 
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the A3 Action Group focused on the prevention of ageing 
related frailty, diseases and functional decline [26-28]. 
Since its inception, the EIP-on-AHA has fostered the 
development of reference sites and synergies between 
these to develop a network of interconnected sites across 
Europe dedicated to achieving its aims [29-31]. In 2016, it 
launched its’ Twinning Support Pilot Scheme to promote 
the scaling-up of good practices between reference sites, 
bringing together 43 twinning organisations from 13 
countries through a series of projects [31]. 
 
This study presents the results of the translation, 
refinement and initial validation of the Qmci screen in 
Portugal as part of the RAPid COmmunity COGnitive 
screening Programme (RAPCOG) twinning project 
developed by four EIP-on-AHA reference sites: Ireland’s 
Collaboration on Ageing (COLLAGE) [32] as originator 
and the Metropolitan Area of Porto (Porto4Ageing; 
Portugal) [33] as, Campania area reference site (Italy) (34) 
and the Catalonia reference site (Barcelona, Catalonia, 
Spain) [35] as adopters. Its overarching goal was to adapt 
and develop an existing CSI for use with any future 
cognitive screening and assessment programmes, 
particularly one that could be computerised to support 
eHealth screening. 
 
II.  METHODOLOGY 
 
 Overview (Milestones) of the RAPCOG 
Twinning Project: Trainers (the developers of the Qmci 
screen) from the originator site in Ireland travelled to two 
adopter sites (Porto in October 2016 and Barcelona in 
February 2017) to provide training to local staff and 
partners from the other two adopter sites. This involved a 
defined review of existing structures and systems in the 
originator country, education sessions and workshops with 
staff. Face-to-face meetings with clinic and community-
based staff were also conducted. Milestones were set for 
trialling the translated version and initiating validation in 
the adopter sites – a central step in showing that the 
instrument and information technology (IT) application 
are acceptable and accurate for use in the adopter sites. 
Translation of the Qmci screen followed by back-
translation happened in advance of the site visits 
(described in detail below; Milestone 1). These were 
discussed and deliberated upon during the face-to-face 
meeting, which served to identify local and cultural issues 
with adaption, adoption and implementation after which a 
plan (protocol) was accepted (Milestone 2). The originator 
site continued to support the validation process and 
provide logistical, statistical and expert clinical support 
for each site (Milestones 3-6). Sampling and trialling in 
the field then proceeded in each site (Milestones 3-6). 
Follow-up meetings were scheduled for the mid-point of 
the initiative (interim – progress meeting – Milestone 5) 
and at the end (Milestone 6). The final meeting was held 
in the originator site in Ireland in June 2017. 
Here we present the outcomes from the 
Portuguese site. A similar, concurrent approach to 
translating and validating Spanish and Catalan versions 
was conducted in primary care in Barcelona and will be 
reported elsewhere once data collection is complete (327 
participants included to date).  
Participants: RAPCOG took advantage of a 
planned study to examine the clinical effectiveness of 
brief screening instruments for use in community settings 
called the Instrumentos Breves para Idosos (IBIS) study 
[36]. IBIS was designed to compare the construct validity 
of Portuguese language versions of the Qmci screen 
(Qmci-P), the Mini-Mental State Examination (MMSE-P) 
[37] and the Montreal Cognitive Assessment (MoCA-P) 
[38, 39]. Scores were also compared with measures of 
activities of daily living (ADL), personality and mood. 
The validation study was conducted with older adults aged 
≥65 years, attending ten day care centres (n=113) and 
residents (n=53) in two long-term care institutions in 
Porto, Portugal who were included using convenience 
sampling. Participants provided consent to take part and 
those who completed screening were then invited to 
complete questionnaires. Demographic data (age, gender 
and education) as well as clinical data on cognition, 
personality, depression and functional status were 
collected during each assessment. Participants provided 
informed consent and the study received ethics approval 
in advance. The IBIS study protocol included the 
following measures: 
 
Outcome measures: Cognition was screened and 
assessed using the Standardised MMSE-P (SMMSE-P) 
[37] and the MoCA-P [38, 39]. The recently translated 
Qmci-P (see Appendix) was also used to investigate 
criterion-related (concurrent) validity. The Qmci-P screen 
has six subtests: orientation (10 points), five word 
registration (5 points), a clock drawing test (15 points), 
one-minute delayed recall (20 points), verbal category 
(semantic) fluency and logical memory, a test of 
immediate verbal recall of a short story [16, 40] to a total 
score of 100 with an established cut-off of 62/100 for 
cognitive impairment (MCI or dementia) [41]. It is a short 
CSI with a median administration time of 4.24 minutes 
[40]. It has superior accuracy to the 6-item CIT [14] and 
the SMMSE [13, 18] and is non-inferior but with a shorter 
administration time compared to the MoCA [15, 21, 23]. 
It also has moderate to strong correlation with the Lawton 
and Brody ADL scale and global measures of cognition 
such as the Clinical Dementia Rating scale and 
Alzheimer`s Disease Assessment Scale-cognitive section 
[42]. 
 In addition to tests of cognition, the 
Neo-FFI 20 personality inventory was scored [43]. This 
assesses the “Big Five” personality traits: Extraversion, 
Agreeableness, Conscientiousness, Neuroticism, and 
Openness to Experience. The Portuguese Version of the 
Geriatric Depression Scale (GDS-P) [44, 45] was used to 
screen for significant depressive symptoms and generate a 
score that classifies participants as “normal" (0-
10),"mildly depressed” (11-20) or "severely depressed” 
(21-30).  Participants who scored 21 or more on the 30-
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point GDS (signifying likely moderate-severe depression), 
were excluded. Health status was measured using the EQ-
5D-3L [46], a standardised measure that provides a simple 
five-item descriptive profile and a single index value, the 
EQ visual analogue scale (EQ-VAS) from 100-0, where 
the endpoints are labelled “Best imaginable health state” 
and “Worst imaginable health state", respectively.  
 
Translation of the Qmci-P: The Qmci-P was 
translated into Portuguese by neuropsychologists with a 
good understanding of English and by a bilingual English 
teacher. This version was then edited and culturally 
adapted by a bilingual Portuguese-English speaker, 
without knowledge of the concepts behind the screening 
tool, to produce a second iteration. This was then back-
translated to English, using the inverse method [47] by 
another bilingual clinical neuropsychologist. The back-
translated version was sent to authors for review and later 
discussed at a research panel meeting including the 
authors of this paper (see 
https://www.linkedin.com/pulse/rapcog-pedro-machado-
dos-santos). Suggestions and edits were incorporated at 
the RAPCOG twinning meeting in Porto to create version 
3.  
Consensual validation was then performed using 
a Portuguese Delphi panel, fluent in English, who 
assessed and compared the different versions in terms of 
semantic, idiomatic and conceptual equivalent of the 
items' contents. If there was no consensus, the majority of 
the five panel members ruled on any issue. However, there 
was consensus on all issues resulting in the definitive 
version of the Qmci-P screen used in this study. A pre-test 
was performed with a sample of five persons during 
clinical consultation who reported that there were no 
issues with the contents of the statements.  
 
Statistical analysis: Data were analysed using 
SPSS version 24.0. The Shapiro–Wilk test, performed to 
test for normality, found that the majority of data were 
non-parametric. Correlations were determined using 
Spearman’s rho with bootstrapping for non-parametric 
data. The Kruskal-Wallis H test compared three or more 
non-normally distributed variables. Cronbach’s Alpha was 
used to measure internal consistency of the CSIs. 
 
 
III.  RESULTS 
 
Overall, 166 people were approached of whom 148 agreed 
to participate and were screened with the Qmci-P. These 
had a median age of 77 years, interquartile range (IQR) 
+/-15 and 64% were female. Of these 148 participants, 
103 completed the full assessment battery with the 
remainder withdrawing stating time constraints or fatigue 
as reasons. Participants completing the assessment battery 
were then scored on the GDS and those scoring ≥21, 
indicating possible active depression, were excluded 
(n=11) leaving a final sample of 93 for analysis. These 
had a median age of 74 years (IQR +/-15), significantly 
younger than all those initially consenting (p=0.03). Their 
demographics and other characteristics are presented in 





Table 1. Socio-demographic characteristics of the final sample 
included (n=93). 
 
 The median Qmci-P screen score of those 
included was 57/100 (IQR +/-26) with a median MoCA of 
21/30 (IQR +/-8) and median SMMSE of  27/30 (IQR +/-
5). Qmci-P screen scores strongly, positively and 
significantly correlated with both the SMMSE (r=0.61, 
95% confidence interval 0.45-0.72, p<0.001) and the 
MoCA (r=0.63, 95% confidence interval 0.36-0.80, 
p<0.001). The correlation between the SMMSE and 
MoCA was also strong (r=0.67, 95% confidence interval 
0.43-0.84, p<0.001). Scatter plots are presented in Figure 
1. Internal consistency of the Qmci-P screen measured 
using Cronbach’s Alpha was 0.82. This compared with 
0.79 for the MoCA and only 0.54 for the SMMSE. The 
median GDS score of those included was 10 +/-10 points. 
There was a gradient effect associated with participant 
GDS scores with statistically significant differences 
between the median Qmci-P screen scores for those with 
GDS scores of 0-14 versus 15-20 and ≥21 (Qmci-P screen 
scores of 58, 47 and 35 respectively, χ2=11, p=0.004), see 
Table 1. This was similar for the SMMSE (χ2=7.6, 
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Fig. 1. Scatter plot demonstrating the correlation between a. The 
Quick Mild Cognitive Impairment (Qmci-Portuguese) screen and 
the Montreal Cognitive Assessment (MoCA), b. The Qmci-
Portuguese and the Standardised Mini-Mental State Examination 
(SMMSE) and c. The SMMSE and MoCA, for all participants 
(n=148). 
 
 Using the established cut-off for the Qmci screen, 
<62/100 [41], the majority (n=58, 62%) of the sample 
screened positive for cognitive impairment (MCI or 
dementia). This compared to 76% with the MoCA using 
the widely used cut-off of <26 (38), which fell to 62% 
when a lower cut point designed to improve diagnostic 
accuracy of <23 was selected. Only 19 (20%) participants 
screened positive for cognitive impairment with the 
SMMSE at its established cut-off of <24 [37]. The 
proportion of participants screening positive for cognitive 
impairment with each of the cognitive screening 
instruments at different published cut-offs is presented in 




Table 2. Comparison of the proportion of participants screening 
positive for cognitive impairment using established cut-offs for the 
Quick Mild Cognitive Impairment (Qmci-Portuguese) screen, 
Montreal Cognitive Assessment (MoCA) and Standardised Mini-
Mental State Examination (SMMSE). 
 
Immediately after completion of the final meeting held in 
the originator site, partners experiences of the Twinning 
project were discussed to finalise the report on the 
Twinning Activity for the European Commission. In 
summary, the three adopter sites collectively reported that 
cultural differences between the countries were a major 
challenge in translating the instruments in a way that the 
results would be consistent between sites. Round table 
discussion through the forum of the twinning support 
scheme was really valued by all. Face-to-face discussion 
facilitated these nuanced discussions akin to a mini Delphi 
consensus panel. In addition, challenges were reported 
with recruiting sufficiently trained staff to validate the 
instrument in each of the adopter countries resulting in the 
need to bring in additional staff from other sites.  Further, 
it is expected that additional resources in terms of funding 
will be required to fully incorporate the translated versions 
into an IT application. Partners skillsets were 
predominantly clinical and other personnel with IT and 
business acumen are now required.   
   
 
IV.  DISCUSSION 
 
 The main goals of this study were to report on the 
EIP-on-AHA RAPCOG Twining initiative (2016-17) 
involving four reference sites geographically dispersed 
across the EU (Ireland, Portugal, Spain – Catalonia - and 
Italy) (31), which aimed to adapt the Qmci screen as a 
brief CSI for use in any future community-based cognitive 
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screening programmes, particularly those that could be 
adapted for use with existing and future eHealth IT 
infrastructure. Here we present the results of the 
translation and initial validation of the Qmci-P for use in 
Portuguese-language countries, exploring its concurrent 
validity against the most commonly used short CSIs in 
Portugal, the MMSE-D and the MoCA-P. The translation 
and adaptation of Qmci screen resulted in the development 
of a Portuguese version that is conceptually equivalent to 
the original. That is, the instrument is natural and 
acceptable and performs in the same way with an 
emphasis on cross-cultural and conceptual, rather than on 
linguistic/literal equivalence.  
The strength of this study is the robust analysis 
used to identify the discriminatory characteristics of the 
Qmci-P screen in comparison to other CSIs, providing 
more accurate results than non-bootstrapped methods, 
especially when analysing smaller sample sizes. The 95 % 
confidence intervals obtained from the bootstrap and the 
asymptotic approach, were in all cases virtually equal. 
This indicates that the intervals are valid. The Qmci-P 
screen demonstrates high internal consistency with a 
Cronbach’s Alpha of 0.82, higher than that of the other 
instruments and in keeping with other studies of the Qmci 
screen (23, 42).  This study also presents its concurrent 
validity against more established CSIs showing moderate, 
positive and significant correlation with the MoCA-P. 
However, given its brevity (3-5mins), (10, 15), it may be 
preferable for use in community settings.  
This case exemplar shows the potential of the 
Commissions’ Twinning Support Scheme to facilitate the 
rapid up-scaling of a good practice initiative and an 
existing commitment under the EIP-on-AHA.  Review of 
the project after the final meeting showed that all 
participants were satisfied with the process, though 
concerns were expressed, particularly in relation to how a 
lack of IT expertise among an academic and clinical 
research group to realise the potential of the instrument as 
an eHealth tool.  The results, nevertheless show the 
potential of such a scheme to produce rapid results. Once 
fully validated and implemented in all the languages of the 
participating reference sites, it is hoped that the new 
solution will help streamline cognitive screening 
assessments in the community in each of the adopted sites. 
This is expected to save time, resources and money if 
evidence-based treatments for dementia emerge, 
strengthening the as yet limited evidence for community-
based cognitive screening (6, 7). Irrespective, it is 
expected that it may lead to improved screening (case-
finding) pathways with more patients receiving prompt 
and timely diagnosis. Since this project ended, new 
opportunities have arisen following discussions with other 
twinning sites linked to the adopters (e.g. Naples, 
Campania site in Italy is also twinned to a reference site in 
Croatia in a different twinning initiative. The Croatian site 
in Zagreb has now agreed to participate area by translating 
and validating the Qmci screen into Croatian (Qmci-Cro):, 
see https://ec.europa.eu/eip/ageing/commitments-
tracker/a3/validation-croatian-version-quick-mild-
cognitive-impairment-screen-qmci-cro-0_en. In addition, 
an EU-funded project called ProEmpower plans to use the 
Qmci screen in four pilot sites – Turkey, Portugal, 
Campania and Murcia.  
 
The study has limitations. First, the diagnosis of MCI and 
dementia were not based on clinical criteria but on a 
battery of assessments, potentially misclassifying 
participants. However, the purpose was not to correlate 
the tools with clinical diagnoses but to examine the 
feasibility of using them in this population of older adults 
and examine their concurrent validity. Participants were 
recruited by convenience sampling. This could have 
created selection bias. Few community-dwellers were 
recruited (only those attending day care centres) 
potentially reducing external generalizability. Finally, the 
validation sample was small likely underpowering the 
study.  
 
V.  CONCLUSION 
 
As health professionals and researchers are faced with a 
growing older population but yet limited assessment time 
and clinical resources, there is a need to develop short 
CSIs for clinical and public health practice. The RAPCOG 
Twinning initiative shows the potential of the EIP-on-
AHA reference sites to quickly up-scale good practice as 
highlighted by the development and validation of the 
Qmci-P screen as part of this pilot scheme. The Qmci-P 
had moderate, positive correlation with two short CSIs, 
commonly used in Portugal, but given its brevity (3-5 
minutes), it may be preferable for use with older adults 
than the MMSE (7-8 minutes) and the MoCA (10-12 
minutes) (15). Further research is now required to 
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